- Report
- April 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- March 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- January 2025
- 207 Pages
Global
From €4552EUR$4,995USD£3,888GBP
- Report
- June 2022
- 200 Pages
Global
From €6835EUR$7,500USD£5,838GBP
- Report
- February 2024
- 135 Pages
Global
From €4329EUR$4,750USD£3,697GBP
- Report
- February 2023
- 83 Pages
Asia Pacific
From €1367EUR$1,500USD£1,168GBP
- Report
- January 2024
- 89 Pages
Global
From €3500EUR$4,114USD£3,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2415EUR$2,650USD£2,063GBP
Zolmitriptan is a medication used to treat migraine headaches. It belongs to a class of drugs known as triptans, which are used to treat moderate to severe migraine pain. Zolmitriptan works by narrowing the blood vessels around the brain, reducing inflammation and relieving pain. It is available in both oral and nasal spray forms. Zolmitriptan is generally well tolerated, with the most common side effects being nausea, dizziness, and fatigue.
The Zolmitriptan market is a subset of the larger Central Nervous System Drugs market. It is a highly competitive market, with a number of different companies offering products. Zolmitriptan is used to treat a wide range of migraine headaches, making it a popular choice for many patients.
Some of the companies in the Zolmitriptan market include GlaxoSmithKline, Novartis, Merck, and Teva Pharmaceuticals. Show Less Read more
